Praxis Precision Medicines has been granted a patent for fused heteroaryl compounds that can prevent or treat diseases related to abnormal sodium ion channel function. This includes neurological disorders like Dravet syndrome and epilepsy, as well as pain and neuromuscular disorders. GlobalData’s report on Praxis Precision Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Praxis Precision Medicines Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Praxis Precision Medicines, Peptide pharmacophores was a key innovation area identified from patents. Praxis Precision Medicines's grant share as of January 2024 was 13%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of diseases related to sodium ion channel dysfunction

Source: United States Patent and Trademark Office (USPTO). Credit: Praxis Precision Medicines Inc

A recently granted patent (Publication Number: US11866439B2) discloses a crystalline form of a compound characterized by specific X-ray powder diffraction patterns and melting points. The crystalline form exhibits distinct diffraction peaks at precise angles, such as 10.7±0.2, 12.3±0.2, 12.6±0.2, 15.8±0.2, 18.6±0.2, and 22.6±0.2 degrees 2?. Additionally, the patent highlights the melting point onset of the crystalline form, determined to be around 107°C, as well as its differential scanning calorimetry curve. The X-ray powder diffraction pattern is obtained using Cu Ka radiation, further emphasizing the specific characteristics of this crystalline form.

Moreover, the patent extends to pharmaceutical compositions incorporating the disclosed crystalline form along with a pharmaceutically acceptable carrier. These compositions are based on the unique properties of the crystalline form, as outlined in various claims within the patent. From compositions containing the crystalline form characterized by specific diffraction patterns to those with defined melting points and calorimetry curves, the patent covers a range of pharmaceutical formulations. The inclusion of the crystalline form in these compositions aims to leverage its distinct attributes for potential therapeutic applications, highlighting the significance of this patented innovation in the pharmaceutical industry.

To know more about GlobalData’s detailed insights on Praxis Precision Medicines, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies